Akcea Therapeutics UK

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, was established in early 2015 and is headquartered in Boston, Massachusetts. Akcea Therapeutics developed an initial presence in the UK in October 2016 and a UK and European head office in Surrey in 2018. It is now on its way to becoming a truly global company with other offices across Europe and the World. We have a robust portfolio of licensed and developmental stage drugs covering multiple targets and diseases, using advanced RNA-targeted antisense oligonucleotides (ASO). Our immediate focus is to make our approved products for hereditary transthyretin amyloidosis (hATTR) and familial chylomicronaemia syndrome (FCS) available to patients throughout the UK.

Want to learn more?

Contact us

CPD Subsectors